|
BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb |
Consulting or Advisory Role - Lilly; Pfizer |
Research Funding - Pfizer |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly |
|
|
Consulting or Advisory Role - Merck Serono |
Research Funding - Merck Serono (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |